CTOs on the Move

Mynosys Cellular Devices

www.zepto-cataract.com

 
Mynosys Cellular Devices, Inc. develops a medical device, Zepto, that is a disposable capsulotomy device. It creates a precise, circular capsulotomy during cataract surgery.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Mynosys Cellular Devices raised $25M on 10/09/2019

Similar Companies

EnteroMedics

EnteroMedics® Inc. is the developer of vBloc® neurometabolic therapy, delivered by a pacemaker-like device called the Maestro® Rechargeable System, a first-in-class weight loss treatment for obesity and obesity related risk factors, such as high blood pressure or high cholesterol levels. vBloc Therapy is a non-anatomy altering or restricting, reversible therapy that allows patients to safely lose weight by helping patients feel less hungry, reduce the amount of food eaten at a meal, and feel full longer in between meals. vBloc Therapy is now approved by the Food and Drug Administration for weight loss in adults with a BMI of 40 to 45 kg/m2 or a BMI of 35 to 39.9 kg/m2 with a related health condition such as high blood pressure or high cholesterol levels.* *Individuals should have first tried to lose weight by diet and exercise in a supervised program within the last 5 years before receiving the Maestro System.

TOPSPINS

TOPSPINS is a Ann Arbor, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MBF Capital Corporation

MBF Capital Corporation is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Saliva Diagnostics Systems

Saliva Diagnostics Systems is a Brooklyn, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.